Title: Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019

Yanli Liu, MD[1,*]; Wenwu Sun, MD[1,*]; Jia Li, PhD[2,*]; Liangkai Chen, PhD[3,*,#]; Yujun Wang, MD[1]; Lijuan Zhang, MD[1]; Li Yu, MD[1,#].

[1] Intensive Care Unit, the Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

[2] Department of Health Technology and Informatics, the Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong PRC.

[3] Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition and Safety, Ministry of Education Key Lab of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

*** The first four authors contributed equally to this article.**

 # Corresponding authors:

Liangkai Chen, Email: clk@hust.edu.cn;

Li Yu, Email: yuliwhzxyy@163.com.

Word count: 2,188

No. of Tables: 3

No. of Figures: 2

Abstract

Background: The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) results in a cluster of coronavirus disease 2019 (COVID-19). We reported the clinical characteristics of COVID-19 patients with acute respiratory distress syndrome (ARDS), and further investigated the treatment and progression of ARDS in COVID-19.

Methods: This study enrolled 109 patients with COVID-19 admitted to the Central Hospital of Wuhan, a designated hospital in Wuhan, China, from January 2 to February 1, 2020. Patients were followed up to February 12, 2020. The clinical data were collected from the electronic medical records. The differences in the treatment and progression with the time and the severity of ARDS were determined.

Results: Among 109 patients, mean age was 55 years, and 59 patients were male. With a median 15 days (range, 4 to 30 days) follow-up period, 31 patients (28.4%) died, while 78 (71.6%) survived and discharged. Of all patients, 53 (48.6%) developed ARDS. Compared to non-ARDS patients, ARDS patients were elder (mean age, 61 years *vs.* 49 years), and more likely to have the coexistent conditions, including diabetes (20.8% *vs.* 1.8%), cerebrovascular disease (11.3% *vs.* 0%), and chronic kidney disease (15.1% *vs.* 3.6%). Compared to mild ARDS patients, those with moderate and severe ARDS had higher mortality rates. No significant effect of antivirus, glucocorticoid, or immunoglobulin treatment on survival was observed in patients with ARDS.

Conclusions: The mortality rate increased with the severity of ARDS in COVID-19, and the effects of current therapies on the survival for these patients were not satisfactory, which needs more attention from clinicians.

Key words: severe acute respiratory syndrome coronavirus 2; coronavirus disease 2019; acute respiratory distress syndrome; clinical feature; mortality.

Introduction

The emergent outbreaks of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain a threat to the public health worldwide [1,2]. As of February 19, 2020, 74,280 cases were confirmed, and 2,008 death cases were recorded in China. The number of confirmed cases in other countries are ascending as well [3-5]. COVID-19 may become a heavy global burden, especially in the low-income and middle-income countries.

Growing studies identified the clinical features of COVID-19 [6-8]. Similar to SARS in 2003, this infectious disease results in the high possibility of the admission to the intensive care unit (ICU) and the mortality [6]. Notably, due to the cytokine cascade within a short period, the critically ill patients with COVID-19 were more likely to develop acute respiratory distress syndrome (ARDS) and receive oxygen treatment [6]. ARDS was the most common complication in COVID-19 patients, with a high mortality rate [6,7]. However, little is known regarding the clinical characteristics, treatment, and progression of COVID-19 patients who developed ARDS.

In this study, we retrospectively reviewed the clinical data of patients with COVID-19 who were admitted to the Central Hospital of Wuhan, and determined the differences in the clinical characteristics between COVID-19 patients with and without ARDS. Additionally, to reveal the evolvement of ARDS in COVID-19, we also investigated the clinical features and therapies of COVID-19 patients at each severity level of ARDS.

Our study might provide new insight into the risk stratification and therapeutic strategy for COVID-19 patients.

Methods

Study Population

Between January 2 and February 1, 2020, 109 patients with COVID-19 admitted to the Central Hospital of Wuhan were consecutively enrolled. The Central Hospital of Wuhan is one of the designated hospitals set up on a temporary basis to receive patients with COVID-19. According to the World Health Organization interim guidance [9], the diagnostic criteria of COVID-19 was based on the virus RNA detection, the clinical characteristics, the chest imaging, and the ruling out common pathogen. Patients with malignant tumors, previous craniocerebral operation, died on admission, or transferred to other medical institutions were excluded. The clinical outcomes of patients were followed up to February 12, 2020. All data were anonymous, and the requirement for informed consent was waived. The Ethics Committees of the Central Hospital of Wuhan approved this study.

Data Collection

Case report forms, nursing records, laboratory findings, and radiological features were reviewed. All data were collected onto the standardized forms from the electronic medical records in the hospital. Two senior physicians independently reviewed the data. Information on demographic data, symptoms, underlying comorbidities, chest

computed tomographic images, and laboratory results were included. All treatment measures were collected during the hospitalization, such as antiviral therapy, antibacterial therapy, corticosteroid therapy, immune support therapy, and respiratory support. The time of disease onset was defined as the day of symptom onset. The time from the first symptom to the fever clinics, hospital admission, and clinical outcomes were recorded. A confirmed respiratory tract specimen was defined as positive for SARS-CoV-2. Repeated tests for SARS-CoV-2 were done in the confirmed patients to show viral clearance before the hospital discharge. The Berlin definition was applied to determine the presence and severity of ARDS [10]. Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA) scores and CURB-65 criteria [11] were determined within 24 hours after admission.

Detection of Coronavirus by Real-Time Reverse Transcription Polymerase Chain Reaction

Throat swab samples were collected from the suspected patients, and the method of virus RNA detection was reported [7]. Briefly, the presence of SARS-CoV-2 in the respiratory specimens was detected by real-time reverse transcription polymerase chain reaction (RT-PCR). Two target genes were used, including open reading frame lab (ORF1ab) and nucleocapsid protein (N), and the sequences were as follows: ORF1ab: forward primer CCCTGTGGGTTTTACACTTAA; reverse primer ACGATTGTGCATCAGCTGA. N: forward primer GGGGAACTTCTCCTGCTAGAAT; reverse primer

CAGACATTTTGCTCTCAAGCTG. The real-time RT-PCR assay was conducted in line with the manufacturer's protocol (Beijing Genomics Institution and Geneodx biotechnology Co. Ltd). Positive test results for two target genes were considered as laboratory-confirmed infection.

Statistical Analysis

Normally distributed continuous variables were presented as mean ± SD, compared by Student's t-test. Skew distributed continuous variables were shown as median (interquartile range [IQR]), analyzed by Mann–Whitney test or Kruskal–Wallis test. Categorical variables were compared by Chi-square test or the Fisher's exact test. Kaplan–Meier methods were used for survival plotting, and log-rank test for comparison of survival curves. The dynamic trajectory in laboratory parameters was plotted using GraphPad Prism 8 (GraphPad Software, Inc). Generalized linear mixed models examined the differences in the laboratory data between ARDS and non-ARDS groups over time. All statistical analysis were performed by the statistical software packages R (http://www.R-project.org, The R Foundation) and the EmpowerStats (http://www.empowerstats.com, X&Y Solutions, Inc., Boston, MA) with a two-sided significance threshold of $P < 0.05$.

Results

Clinical Characteristics

A total of 109 patients with COVID-19 were included in the current study. The baseline clinical parameters of overall COVID-19 patients and COVID-19 patients with and without ARDS were summarized in **Table 1**. Mean age of all subjects was 55 years (IQR, 43-66 years; range, 22-94 years), and 54.1% of all patients were male. The most common symptom at the illness onset was fever (82.6%), followed by dry cough (61.5%) and fatigue (56.9%). Seventy-six patients (69.7%) had underlying comorbidities, including hypertension (33.9%), diabetes (11.0%), and chronic kidney disease (9.2%). The first virus RNA detection rate was 24.8% in the fever clinics, and all patients were reconfirmed by repeated virus RNA testing after admission. Among 109 patients, 91.7% of them had bilateral involvement of the chest radiographs, and 28 patients (25.7%) received high-flow nasal oxygen ventilation, while 31 (28.4%) died.

Compared with non-ARDS patients with COVID-19, ARDS patients were elder (mean age, 61 years *vs.* 49 years), and more likely to have coexistent diabetes (20.8% *vs.* 1.8%), cerebrovascular disease (11.3% *vs.* 0%), and chronic kidney disease (15.1% *vs.* 3.6%). The bilateral involvement in the chest radiographs was identified in all ARDS patients, but in 83.9% non-ARDS patients. The likelihood to receive high-flow nasal ventilation for ARDS patients (49.1%) was significantly higher than that for non-ARDS patients (3.6%). The mortality rate in ARDS patients (49.1%) was also significantly higher than that in non-ARDS patients (8.9%).

160 **Disease Severity Scores and Laboratory Findings in COVID-19 Patients With and**
161 **Without ARDS**

162 The disease severity evaluation and laboratory examination of non-ARDS and ARDS
163 patients with COVID-19 on admission were shown in **Table 2**. Compared with non-
164 ARDS subjects, ARDS subjects had significantly higher disease severity on the day of
165 hospital admission (all *P* values <0.001 for CURB-65, SOFA, and APACHE II). ARDS
166 patients were more likely accompanied by lymphopenia on admission (*P* value <0.001).
167 Besides, the levels of lactate, neutrophil count, C-reactive protein (CRP), and
168 procalcitonin were significantly higher in ARDS patients than in non-ARDS patients
169 (median lactate level, 1.6 *vs.* 1.1 mmol/L; median neutrophil count level, 4.1 *vs.* 3.2
170 $\times 10^9$/L; median CRP level, 4.9 *vs.* 2.0 mg/dL; median procalcitonin level, 0.15 *vs.* 0.06
171 ng/mL). Significant increased levels of blood urea nitrogen, serum fibrinogen, D-dimer,
172 and lactate dehydrogenase in ARDS patients were observed, compared with those in
173 non-ARDS patients (all *P* values <0.05).

174

175 As described in **Figure 1**, the dynamic trajectory in nine laboratory parameters were
176 tracked on Day 1, 3, 7 and 14, respectively. Significant differences in the levels of
177 neutrophil count, lymphocyte count, CRP, procalcitonin, and D-dimer were found
178 between ARDS and non-ARDS patients with COVID-19 (all *P* values <0.05). From
179 Day 1 to 14, ARDS patients had significantly lower lymphocyte count levels, while the
180 levels of other laboratory findings were higher in ARDS patients.

181

182 **Clinical Profile and Progression of COVID-19 Patients With ARDS**

183 According to the severity of ARDS, we further analyzed the clinical features, treatments
184 and progression of 53 COVID-19 patients with ARDS. As presented in **Table 3**, the
185 increase in APACHE II, SOFA, and CURB criteria scores occurred concomitantly with
186 the severity of ARDS (all *P* values <0.001). The levels of lactate, blood urea nitrogen,
187 D-dimer, and lactate dehydrogenase ascended with the severity of ARDS (all *P* values
188 <0.05), whereas the lymphocyte count levels decreased (*P* value = 0.045). Patients with
189 moderate ARDS were the most likely to receive glucocorticoid therapy (*P* value = 0.02)
190 and high-flow nasal oxygen ventilation (*P* value <0.001), with the longest stays in the
191 hospital (*P* value = 0.03). Compared to patients with mild ARDS, those with moderate
192 and severe ARDS had higher mortality rates (*P* value <0.001).

193

194 Subsequent survival analysis was shown in **Figure 2**. We found that the antivirus,
195 glucocorticoid, or immunoglobulin treatment did not have any significant effect on the
196 survival of COVID-19 patients with ARDS (all log-rank tests *P* >0.05).

197

198 **Discussion**

199 In the present study of ARDS progression in COVID-19, we firstly identified the
200 differences in the clinical manifestations between COVID-19 patients with and without
201 ARDS. Second, the clinical characteristics of COVID-19 patients varied with the
202 severity of ARDS. High mortality rates were found in patients with moderate and severe
203 ARDS. Third, we did not observe any apparent effect of the current therapeutic

204 interventions on the in-hospital survival of COVID-19 patients with ARDS. Our
205 findings might highlight the clinical significance in the enhanced attention towards
206 COVID-19 patients at high risks of ARDS.
207
208 To the best of our knowledge, this study is the first to investigate the clinical features
209 and progression of SARS-CoV-2 infected patients with ARDS. We revealed that elder
210 patients, or complicated by diabetes, cerebrovascular disease, and chronic kidney
211 disease, were more likely to develop ARDS. This finding might further explain the
212 significant association of age and comorbidity conditions with the poor clinical
213 outcomes in a previous COVID-19 study [7]. In addition, the elevated levels of neutrophil
214 count, CRP, procalcitonin and D-dimer, but the decreased lymphocyte count levels,
215 were detected in patients with ARDS, rather than those without ARDS. Similarly, the
216 levels of lactate and D-dimer increased with the progression of ARDS due to SARS-
217 CoV-2, while severer lymphopenia occurred over time. Our investigations into these
218 laboratory indicators were comparable with other COVID-19 studies [6,7,12], suggesting
219 that cytokine cascade, excessive inflammatory reaction, and coagulation dysfunction
220 might evolve in the course of ARDS resulted from SARS-CoV-2.
221
222 Notably, our understanding of this ARDS progression could be furthered by a recent
223 autopsy report on a 50-year-old COVID-19 patient with ARDS [13], which was
224 highlighted by the inflammatory infiltration of lymphocytes in both lungs and the
225 immune hyperactivation in the patient. Interestingly, no obvious heart injury occurred

226 in this patient, while the liver injury might be caused by SARS-CoV-2 infection or
227 medication use [13]. These pathological results were concordant with our clinical
228 observation of a dysregulated inflammatory and immune state in COVID-19 patients
229 with ARDS, which might in turn help to guide our medical therapy.
230
231 The medical management of ARDS has advanced remarkably during the past decades
232 [14]. Yet, the general mortality rates of ARDS caused by all etiologies fluctuated from 11%
233 to 87% [15]. In our study, most patients with COVID-19 received antibiotics and antivirus
234 treatment, while over half of them were given by glucocorticoid and intravenous
235 immunoglobulin therapies. Moderate to severe ARDS patients were more likely to use
236 high-flow nasal oxygen ventilation. Unfortunately, the mortality rate was extremely
237 high in severe ARDS patients with COVID-19. Notably, the survival of COVID-19
238 patients with ARDS was not improved by the antivirus, glucocorticoid, or
239 immunoglobulin treatment. We postulated that two causes might interpret these results:
240 First, because of the SARS-CoV-2 outbreak within a short period, the designated
241 hospitals were fast and easily overloaded, with inadequate medical facilities and
242 insufficient medical staff. Second, in this study, we excluded some COVID-19 patients
243 who had transferred to other hospitals for advanced life support. However, our findings
244 were still meaningful. As the low-income and middle-income countries are more
245 vulnerable to the lack of medical resources, the mortality rate of infectious diseases
246 may be even higher. Therefore, from a policy perspective, the government should
247 provide capital, technology, and manpower to curb the epidemic. Meanwhile, in the

248 front-line epidemic area, limited medical resources should be allocated reasonably and
249 effectively.
250
251 The present study is subjected to several limitations. Due to the retrospective nature of
252 the present study, a systematic selection bias could be introduced. We could not
253 completely address the residual confounding factors as well. Although our laboratory
254 observations showed the significant changes with the time and the severity of ARDS,
255 the clinical predictive value remained to be determined. In addition, our results on the
256 effect of the current treatments should be considered with caution, and high-quality
257 clinical interventional studies are needed. Meanwhile, the benefits of the invasive
258 ventilation therapy on the disease prognosis should be further investigated. In the future,
259 a multi-center and follow-up study with a larger cohort is eagerly warranted.
260
261 **Conclusions**
262 In the current study from one of the designated hospitals in Wuhan, China, the
263 significant changes with the time and the severity of ARDS were observed in COVID-
264 19 patients. Moreover, COVID-19 patients with moderate and severe ARDS had high
265 mortality rates. The current medical treatments might not have a significant effect on
266 the in-hospital survival of COVID-19 patients with ARDS. Our observations might help
267 to guide the risk stratification and therapeutic strategy for COVID-19 patients.
268

Acknowledgement:

We deeply regret and mourn all the lives lost in this disaster of SARS-CoV-2, including our dearest colleague Dr. Wenliang Li. We would like to express our deepest respect to all the people who are currently fighting against the outbreak of COVID-19.

Conflict of Interest Disclosures:

The authors declared no conflict of interest.

Founding/Support:

This study was supported by the Health and Family Planning Commission of Wuhan Municipality, grant number WX18A02.

Role of the Founder/Sponsor:

The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Authors Contributions:

Dr. Chen and Dr. Yu had full access to all the data in the study, and took responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Liu, Sun, Chen, Yu.

Acquisition, analysis, or interpretation of data: Sun, Liu, Li, Chen.

Drafting of the manuscript: Li, Liu.

Critical revision of the manuscript for important intellectual content: Wang, Zhang, Chen, Yu.

Statistical analysis: Chen.

Obtained funding: Yu.

Supervision: Chen, Yu.

297 **References**

298 1. Hui DS, E IA, Madani TA, et al. The continuing 2019-nCoV epidemic threat of
299 novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in
300 Wuhan, China. *Int J Infect Dis* 2020; **91**: 264-6.
301 2. Velavan TP, Meyer CG. The COVID-19 epidemic. *Trop Med Int Health* 2020.
302 3. Team C-NIRS. COVID-19, Australia: Epidemiology Report 3 (Reporting week
303 ending 19:00 AEDT 15 February 2020). *Commun Dis Intell (2018)* 2020; **44**.
304 4. Smith N, Fraser M. Straining the System: Novel Coronavirus (COVID-19) and
305 Preparedness for Concomitant Disasters. *Am J Public Health* 2020: e1-e2.
306 5. Habibzadeh P, Stoneman EK. The Novel Coronavirus: A Bird's Eye View. *Int J*
307 *Occup Environ Med* 2020; **11**(2): 65-71.
308 6. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019
309 novel coronavirus in Wuhan, China. *Lancet* 2020; **395**(10223): 497-506.
310 7. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients
311 With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020.
312 8. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of
313 Novel Coronavirus-Infected Pneumonia. *N Engl J Med* 2020.
314 9. World Health Organization. Clinical management of severe acute respiratory
315 infection when novel coronavirus (nCoV) infection is suspected: interim guidance.
316 https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-
317 cov.pdf?sfvrsn=bc7da517_2. Published January 28, 2020. Accessed February 12, 2020.
318 10. Force ADT, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress
319 syndrome: the Berlin Definition. *JAMA* 2012; **307**(23): 2526-33.
320 11. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired
321 pneumonia severity on presentation to hospital: an international derivation and
322 validation study. *Thorax* 2003; **58**(5): 377-82.
323 12. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with
324 the 2019 novel coronavirus indicating person-to-person transmission: a study of a
325 family cluster. *Lancet* 2020; **395**(10223): 514-23.
326 13. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with
327 acute respiratory distress syndrome. *The Lancet Respiratory Medicine*.
328 14. Peck TJ, Hibbert KA. Recent advances in the understanding and management
329 of ARDS. *F1000Res* 2019; **8**.
330 15. Maca J, Jor O, Holub M, et al. Past and Present ARDS Mortality Rates: A
331 Systematic Review. *Respir Care* 2017; **62**(1): 113-22.

332

333 **Table 1. Baseline clinical features of subjects with COVID-19.**

	No. (%)			
	Total (*n* = 109)	**Non-ARDS (*n* = 56)**	**ARDS (*n* = 53)**	***P*-value[a]**
Age, median (IQR), y	55 (43-66)	49 (37-59)	61 (52-70)	**<0.001**
Male	59 (54.1)	31 (55.4)	28 (52.8)	0.79
Entering complaint				
Fever	90 (82.6)	48 (85.7)	42 (79.2)	0.37
Dry cough	67 (61.5)	36 (64.3)	31 (58.5)	0.53
Fatigue	62 (56.9)	26 (46.4)	36 (67.9)	**0.02**
Stethalgia	7 (6.4)	4 (7.1)	3 (5.7)	0.75
Diarrhea	12 (11.0)	6 (10.7)	6 (11.3)	0.92
Comorbidities				
COPD	4 (3.7)	2 (3.6)	2 (3.8)	>0.99
Hypertension	37 (33.9)	16 (28.6)	21 (39.6)	0.22
Diabetes	12 (11.0)	1 (1.8)	11 (20.8)	**0.002**
Cardiovascular disease	7 (6.4)	4 (7.1)	3 (5.7)	>0.99
Cerebrovascular disease	6 (5.5)	0 (0.0)	6 (11.3)	**0.01**
Chronic kidney disease	10 (9.2)	2 (3.6)	8 (15.1)	**0.049**
Onset of symptom to fever clinics, median (IQR), d	4 (2-6)	4 (2-7)	4 (2-6)	0.88
Onset of symptom to hospital admission, median (IQR), d	7 (5-9)	7 (5-9)	7 (5-9)	0.58
Hospital stays, median (IQR), d	15 (11-24)	15 (9-27)	16 (11-23)	0.41
Nucleic acid test (+) in fever clinics	27 (24.8)	12 (21.4)	15 (28.3)	0.41
Bilateral involvement of chest radiographs	100 (91.7)	47 (83.9)	53 (100)	**0.002**
Fever clinics treatment				
Antibiotics	105 (96.3)	55 (98.2)	50 (94.3)	0.35

Antivirus	105 (96.3)	55 (98.2)	50 (94.3)	0.35
Glucocorticoid therapy	43 (39.4)	20 (35.7)	23 (43.4)	0.41
Intravenous immunoglobulin	32 (29.4)	19 (33.9)	13 (24.5)	0.28
In-patient treatment				
Antibiotics	106 (97.2)	53 (94.6)	53 (100.0)	0.24
Antivirus	107 (98.2)	55 (98.2)	52 (98.1)	>0.99
Glucocorticoid therapy	72 (66.1)	35 (62.5)	37 (69.8)	0.42
Intravenous immunoglobulin	61 (56.0)	32 (57.1)	29 (54.7)	0.80
High-flow nasal ventilation	28 (25.7)	2 (3.6)	26 (49.1)	**<0.001**
Death	31 (28.4)	5 (8.9)	26 (49.1)	**<0.001**

Abbreviations: ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; IQR, interquartile range;
[a] *p* values indicate differences between non-ARDS and ARDS patients.

337 **Table 2. Severity of COVID-19 and laboratory tests in Non-ARDS and ARDS subjects.**

	Normal range	Median (IQR)			*P*-value[a]
		Total (*n* = 109)	Non-ARDS (*n* = 56)	ARDS (*n* = 53)	
Severity of illness scores and blood gas analysis on admission to hospital					
CURB-65	NA	0 (0-1)	0 (0-1)	1 (0-2)	**<0.001**
SOFA	NA	2 (1-4)	1 (0-1)	4 (2-5)	**<0.001**
APACHE II	NA	4 (2-8)	2 (1-3)	8 (5-10)	**<0.001**
Lactate, mmol/L	0.5-1.6	1.3 (0.8-2.0)	1.1 (0.8-1.6)	1.6 (1.1-2.2)	**<0.001**
PaO_2:FiO_2, mm Hg	400-500	296 (142-435)	475 (398-524)	145 (108-250)	**<0.001**
Laboratory findings on admission to hospital					
White blood cell count, $\times 10^9$/L	3.5-9.5	5.2 (4.0-7.0)	4.9 (3.8-6.2)	5.4 (4.5-8.0)	0.053
Neutrophil count, $\times 10^9$/L	1.8-6.3	3.6 (2.8-5.6)	3.2 (2.4-4.2)	4.1 (3.1-7.1)	**0.004**
Lymphocyte count, $\times 10^9$/L	1.1-3.2	0.9 (0.5-1.2)	1.0 (0.8-1.4)	0.7 (0.4-1.1)	**<0.001**
C-reactive protein, mg/dL	0-0.5	3.1 (1.1-5.4)	2.0 (0.9-3.2)	4.9 (2.7-6.5)	**<0.001**
Procalcitonin, ng/mL	<0.05	0.09 (0.06-0.20)	0.06 (0.05-0.09)	0.15 (0.08-0.37)	**<0.001**
Blood urea nitrogen, mmol/L	2.8-8	4.3 (3.3-6.5)	3.5 (2.9-4.8)	5.5 (4.0-7.1)	**<0.001**
Creatinine, μmol/L	57-111	65 (55-82)	64 (52-80)	67 (55-83)	0.42
Total bilirubin, mmol/L	0-21	9.0 (6.5-13.4)	8.3 (6.8-11.7)	10.5 (6.2-14.8)	0.23
Alanine aminotransferase, U/L	9-50	23 (15-36)	23 (14-41)	24 (16-31)	0.82
Aspartate aminotransferase, U/L	15-40	30 (21-40)	29 (19-38)	31 (25-44)	0.17
Fibrinogen, g/L	2-4	3.1 (2.7-3.6)	2.9 (2.7-3.3)	3.4 (2.9-3.9)	**0.001**
D-dimer, mg/L	0-500	570 (300-1178)	370 (250-650)	940 (470-1905)	**<0.001**
Lactate dehydrogenase, U/L	135-225	238 (185-341)	209 (183-267)	264 (190-448)	**0.011**
Creatine kinase, U/L	<190	91 (52-178)	100 (53-183)	83 (49-169)	0.29

Creatine kinase–MB, U/L	<25	9.0 (6.1-14.8)	8.5 (6.0-12.5)	10.4 (7.0-15.1)	0.28

Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation II; ARDS, acute respiratory distress syndrome; FiO_2, fraction of inspired oxygen; IQR, interquartile range; NA, not available; PaO_2, partial pressure of oxygen; SOFA, Sequential Organ Failure Assessment

[a] *p* values indicate differences between non-ARDS and ARDS patients.

342 **Table 3. Clinical characteristics, laboratory findings, and treatment according to the severity of ARDS.**

	Normal range	Median (IQR)			*P*-value[a]
		Mild ARDS (*n* = 19)	Moderate ARDS (*n* = 24)	Severe ARDS (*n* = 10)	
Age, y	NA	52 (46-63)	65 (57-70)	67 (55-71)	**0.04**
Severity of illness scores and blood gas analysis on admission to hospital					
CURB-65	NA	0 (0-1)	1 (1-2)	2 (1-3)	**<0.001**
SOFA	NA	2 (2-3)	4 (3-5)	6 (5-6)	**<0.001**
APACHE II	NA	3 (2-6)	8 (7-12)	10 (8-13)	**<0.001**
Lactate, mmol/L	0.5-1.6	1.2 (0.8-1.7)	1.8 (1.1-2.3)	5.2 (2.0-10.0)	**<0.001**
PaO_2:FiO_2, mm Hg	400-500	276 (247-280)	140 (117-153)	85 (57-88)	**<0.001**
Laboratory findings on admission to hospital					
White blood cell count, ×109/L	3.5-9.5	4.6 (3.8-5.0)	7.3 (5.2-10.5)	7.0 (4.6-8.0)	**0.006**
Neutrophil count, ×109/L	1.8-6.3	3.2 (2.3-3.8)	6.0 (4.2-9.0)	5.3 (3.7-7.3)	**0.002**
Lymphocyte count, ×109/L	1.1-3.2	0.9 (0.7-1.3)	0.6 (0.4-0.9)	0.5 (0.4-0.8)	**0.045**
C-reactive protein, mg/dL	0-0.5	4.1 (2.2-5.9)	4.1 (1.9-9.7)	6.7 (5.5-12.2)	**0.027**
Procalcitonin, ng/mL	<0.05	0.10 (0.08-0.21)	0.16 (0.08-0.55)	0.28 (0.22-1.52)	0.09
Blood urea nitrogen, mmol/L	2.8-8	4.5 (3.5-6.1)	5.6 (4.5-7.7)	7.1 (6.0-8.0)	**0.03**
Creatinine, μmol/L	57-111	67 (58-74)	65 (54-99)	70 (55-80)	0.89
Total bilirubin, mmol/L	0-21	7.9 (5.8-10.4)	13.2 (9.3-18.6)	13.2 (6.2-13.5)	0.07
Alanine aminotransferase, U/L	9-50	24 (15-34)	24 (21-27)	21 (15-32)	0.90
Aspartate aminotransferase, U/L	15-40	29 (21-43)	34 (27-44)	29 (27-36)	0.45
Fibrinogen, g/L	2-4	3.3 (2.8-3.6)	3.4 (2.9-4.3)	3.6 (3.4-4.1)	0.41
D-dimer, mg/L	0-500	330 (220-798)	1220 (695-4035)	1385 (985-7550)	**<0.001**

Lactate dehydrogenase, U/L	135-225	190 (166-238)	347 (255-504)	458 (286-549)	**0.001**
Creatine kinase, U/L	<190	69 (44-119)	92 (58-185)	66 (53-188)	0.49
Creatine kinase–MB, U/L	<25	8.0 (6.5-11.6)	11.1 (6.8-16.1)	10.9 (8.9-12.0)	0.37
In-patient treatment, *n* (%)					
Ribavirin	NA	18 (94.7)	18 (75.0)	10 (100.0)	0.08
Oseltamivir	NA	5 (26.3)	8 (33.3)	1 (10.0)	0.43
Arbidol	NA	3 (15.8)	2 (8.3)	1 (10.0)	0.85
Glucocorticoid therapy	NA	9 (47.4)	21 (87.5)	7 (70.0)	**0.02**
Intravenous immunoglobulin	NA	13 (68.4)	9 (37.5)	7 (70.0)	0.08
High-flow nasal ventilation, *n* (%)	NA	1 (5.3)	19 (79.2)	6 (60.0)	**<0.001**
Hospital stays, d	NA	18 (13-25)	18 (15-25)	11 (10-13)	**0.03**
Death, *n* (%)	NA	1 (5.3)	15 (62.5)	10 (100.0)	**<0.001**

Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation II; ARDS, acute respiratory distress syndrome; FiO_2, fraction of inspired oxygen; IQR, interquartile range; NA, not available; PaO_2, partial pressure of oxygen; SOFA, Sequential Organ Failure Assessment

[a] *p* values indicate differences among mild, moderate, and severe ARDS patients.

347 **Figure legends**

348

349 Figure 1. Timeline charts illustrate the laboratory parameters in 109 patients with COVID-19 (56 non-ARDS and 53 ARDS) on day 1, day 3, day

350 7, and day 14 after admission. The dash lines in black show the upper normal limit of each parameter, and the dash line in red shows the lower

351 normal limit of lymphocyte count.

352 * P <0.05 for non-ARDS *vs.* ARDS.

353

354 Figure 2. Kaplan-Meier survival curves for 53 COVID-19 patients concurrent ARDS. (A) Ribavirin; (B) Oseltamivir; (C) Arbidol; (D)

355 Glucocorticoid therapy; (E) Intravenous immunoglobulin.


P = 0.06
White blood cell count, ×10⁹/L
ARDS
Non-ARDS
P = 0.03
Neutrophil count, ×10⁹/L
ARDS
Non-ARDS
P <0.01
Lymphocyte count, ×10⁹/L
Non-ARDS
ARDS
P <0.01
C-reactive protein, mg/dL
ARDS
Non-ARDS
P = 0.04
Procalcitonin, ng/mL
ARDS
Non-ARDS
P = 0.11
Total bilirubin, mmol/L
ARDS
Non-ARDS
P = 0.18
Creatinine, μmol/L
ARDS
Non-ARDS
P = 0.03
D-dimer, mg/L
ARDS
Non-ARDS
P = 0.24
Creatine kinase–MB, U/L
ARDS
Non-ARDS
Day 1
Day 3
Day 7
Day 14


A
Ribavirin No Yes
Survival probability
p = 0.42
Follow−up, days
Number at risk
Ribavirin
7 7 6 4 4 4
46 42 25 15 7 3
B
Oseltamivir No Yes
p = 0.095
Number at risk
Oseltamivir
39 35 20 11 4 1
14 14 11 8 7 6
C
Arbidol No Yes
p = 0.19
Number at risk
Arbidol
47 43 30 19 11 7
6 6 1 0 0 0
D
Glucocorticoid therapy No Yes
p = 0.56
Number at risk
Glucocorticoid therapy
16 15 8 4 2 2
37 34 23 15 9 5
E
Intravenous immunoglobulin No Yes
p = 0.51
Number at risk
Intravenous immunoglobulin
24 23 17 12 7 5
29 26 14 7 4 2